BRCA1 and breast carcinoma: For this reason, the ESMO guidelines do not recommend the use of the multigene next-generation sequencing (NGS) of tumors in breast cancer [75], since PARP inhibitors are only approved for germline BRCA1/2 mutations and since the Solar-1 trial enrolled patients selected for certain hot-spot PI3KCA mutations that can be detected by targeted sequencing.